A Robotic Leap Into Heart Surgery

FDA clears Intuitive’s da Vinci 5 for cardiac use, expanding minimally invasive options for complex heart procedures

18 Mar 2026

Robotic heart surgery just crossed an important line. On January 26, 2026, the FDA cleared Intuitive Surgical’s da Vinci 5 for a broad set of minimally invasive cardiac procedures, giving the company a fresh opening in one of medicine’s most demanding specialties.

The clearance covers mitral valve repair, internal mammary artery mobilization for cardiac revascularization, atrial septal defect repair, and left atrial appendage closure. That matters because traditional open-heart surgery often means splitting the breastbone, followed by considerable pain, a higher risk of complications, and a long recovery. By contrast, the da Vinci 5 is designed to let surgeons work through small incisions, offering a less punishing route to complex heart repairs.

For Intuitive, the move is also a return. The company helped introduce robotic cardiac surgery to US hospitals more than 20 years ago, then shifted its attention to faster-growing fields such as urology and oncology. Now it is coming back with a more advanced system, one that captures more than 1,000 data points per second for each instrument and ties them into a digital platform for planning, guidance, and post-operative analysis.

The commercial opportunity is hardly niche. Intuitive says about 160,000 procedures each year in the US and South Korea fall within the newly cleared scope. Still, the company is not racing into a nationwide rollout. It plans to work with a select group of US hospitals through 2026, building cardiac programs with focused training, specialized instruments, and new clinical evidence.

That measured approach makes sense. Cardiac surgery leaves little room for error, and hospitals as well as insurers will want proof that the technology delivers on outcomes, efficiency, and cost.

The timing is notable, too. Surgical robotics is entering a more competitive era, with Medtronic logging its first US commercial robotic procedure in February 2026 and Johnson & Johnson still moving its platform through regulatory review. By stepping into cardiac care now, Intuitive is claiming territory that no rival robotic system currently serves in the US. For patients who still face the prospect of open-heart surgery, that could be the clearest sign yet that a less invasive future is moving closer to the table.